Advertisement

Topics

"A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects" Drugs and Medication Database

22:47 EST 23rd February 2019 | BioPortfolio

Here are the most relevant "A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects" Drugs and Medications that we have found in our database.

More Information about "A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects" on BioPortfolio

We have published hundreds of A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects news stories on BioPortfolio along with dozens of A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects Clinical Trials and PubMed Articles about A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects Companies in our database. You can also find out about relevant A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects Drugs and Medications on this site too.

Showing "Phase Safety Immunogenicity Study Seronegative Subjects" Drugs and Medications, all 23

Possibly Relevant

Nulojix [e.r. squibb & sons, l.l.c.]

These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX. NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011

Aimovig [amgen inc]

These highlights do not include all the information needed to use AIMOVIG safely and effectively. See full prescribing information for AIMOVIG. AIMOVIG (erenumab-aooe) injection, for subcutaneous use Initial U.S. Approval: 2018

Sylvant [janssen biotech, inc.]

These highlights do not include all the information needed to use SYLVANT safely and effectively. See full prescribing information for SYLVANT. SYLVANT (siltuximab) for injection, for intravenous use Initial U.S. Approval: 2014

Kanuma [alexion pharmaceuticals, inc.]

These highlights do not include all the information needed to use KANUMA safely and effectively. See full prescribing information for KANUMA. KANUMA (sebelipase alfa) injection, for intravenous useInitial U.S. Approval: 2015

Iclusig [millennium pharmaceuticals, inc.]

These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG(ponatinib) tablets, for oral use Initial U.S. Approval: 2012

Zinplava [merck sharp & dohme corp.]

These highlights do not include all the information needed to use ZINPLAVA safely and effectively. See full prescribing information for ZINPLAVA. ZINPLAVA™ (bezlotoxumab) injection, for intravenous use Initial U.S. Approval: 2016

Emgality [eli lilly and company]

These highlights do not include all the information needed to use EMGALITY safely and effectively. See full prescribing information for EMGALITY.EMGALITY (galcanezumab-gnlm) injection, for subcutaneous useInitial U.S. Approval: 2018

Jetrea [thrombogenics inc.]

These highlights do not include all the information needed to use JETREA safely and effectively. See full prescribing information for JETREA JETREA (ocriplasmin) injection, for intravitreal injectionInitial U.S. Approval: 2012

Ajovy [teva pharmaceuticals usa, inc.]

These highlights do not include all the information needed to use AJOVY safely and effectively. See full prescribing information for AJOVY.AJOVY (fremanezumab-vfrm) injection, for subcutaneous useInitial U.S. Approval: 2018

Amantadine hydrochloride [physicians total care, inc.]

NA

Revcovi [leadiant biosciences, inc.]

These highlights do not include all the information needed to use REVCOVI™ safely and effectively. See full prescribing information for REVCOVI. REVCOVI (elapegademase-lvlr) injection, for intramuscular use Initial U.S. Approval: 2018

Amantadine hydrochloride [morton grove pharmaceuticals, inc.]

AMANTADINE HYDROCHLORIDE ORAL SOLUTION, USP50 mg/5 mL

Amantadine hydrochloride [mikart, inc.]

Amantadine hydrochloride [hi-tech pharmacal co., inc.]

Amantadine Hydrochloride Oral Solution, USP

Amantadine hydrochloride [preferred pharmaceuticals inc.]

Amantadine Hydrochloride Oral Solution, USP

Amantadine hydrochloride [upsher-smith laboratories, llc]

Amantadine Hydrochloride Tablets

Amantadine hydrochloride [atlantic biologicals corps]

AMANTADINE HYDROCHLORIDE ORAL SOLUTION, USP 50 mg/5 mL

Amantadine hydrochloride [newgen pharmaceuticals llc]

NA

Amantadine hydrochloride [pharmaceutical associates, inc.]

Amantadine Hydrochloride Oral Solution USP 50 mg/5 mL

Amantadine hydrochloride [cipla usa inc.]

Amantadine Hydrochloride Tablets, 100mg Rx only

Amantadine hydrochloride [cardinal health, inc.]

Amantadine Hydrochloride Oral Solution USP 50 mg/5 mL

Amantadine hydrochloride [carilion materials management]

Amantadine Hydrochloride Oral Solution USP 50 mg/5 mL

Amantadine hydrochloride [unit dose services]

Amantadine Hydrochloride Oral Solution USP 50 mg/5 mL



Advertisement
Quick Search
Advertisement
Advertisement